Christoph van Amsterdam

Over the years, our company gave me the great opportunity to work scientifically in different areas of research, e.g. in vivo and in vitro, in central nervous and cardiovascular systems and in diabetes

Perspective

Over the years, our company gave me the great oppertunity to work scientifically in different areas of research, e.g. in vivo and in vitro, in central nervous and cardiovascular systems and in diabetes and metabolism. This has included the establishment of new labs and departments and the contribution to a huge number of drug projects in different roles and responsibilities. In safety pharmacology, I am trying to to improve the understanding of mechanisms of potential human pharmacodynamic safety liabilities. The challenging aspect of this young discipline is to build on my knowledge, e.g. in pharmacology and physiology, and to develop it further to ensure that our company's products do not have undesirable pharmacodynamic effects on important physiological functions. It is this diversity, which makes safety pharmacology fascinating and drives motivation and curiousity.

Over the years, our company gave me the great opportunity to work scientifically in different areas of research, e.g. in vivo and in vitro, in central nervous and cardiovascular systems and in diabetes and metabolism.

Christoph van Amsterdam

Head, Early Safety Pharmacology

Profile

Joined Merck KGaA, Darmstadt, Germany: 1995

Key research fields and topics:

  • Investigation of potential undesirable pharmacodynamic effects of a new chemical entity (NCE) or biotechnology-derived product for human use on physiological functions in relation to exposure in the therapeutic range and above

CV & Scientific activities

CV: Education

CV: Education

CV: Professional Career

CV: Professional Career

References

Publications 

  • D. Hermann and C. van Amsterdam, Analysis of spontaneous hippocampal activity allows sensitive detection of acetylcholine-mediated effects, J Pharm Tox Meth 71, 54, 2015
  • C. van Amsterdam and C. A. Seyfried,Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output,Psychopharmacology 231, 2547, 2014
  • A. Vernaleken, M. Veyhl, V. Gorboulev, G. Kottra, D. Palm, B. Burckhardt, G. Burckhardt, R. Pipkorn, N. Beier, C. van Amsterdam and H. Koepsell,Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity,J. Biol. Chem. 282, 28501, 2007
  • T. Heinrich, H. Böttcher, H. Prücher, R. Gottschlich, K. Ackermann and C .van Amsterdam,1-(1-Phenethylpiperidin-4-yl)-1-phenylethanols as potent and highly selective 5-HT2A antagonists,ChemMedChem. 1, 245, 2006
  • W.W.K.R. Mederski, B. Cezanne, C. van Amsterdam, K.-U. Bühring, D. Dorsch, J. Gleitz, J. März and C. Tsaklakidis,Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa,Bioorg. Med. Chem. 14, 5817-5822, 2004
  • T. Heinrich, H. Böttcher, R. Gericke, G. D. Bartoszyk, S. Anzali, C. A. Seyfried,H. E. Greiner and C. van Amsterdam,Synthesis and structure-activity relationship in a class of indolebutylpiperazines as dual,5-HT(1A) receptor agonists and serotonin reuptake inhibitors,J. Med. Chem. 47, 4684-4692, 2004
  • T. Heinrich, H. Böttcher, G. D. Bartoszyk, , H. E. Greiner, and C. A. Seyfried and C. van Amsterdam,Indolebutylamines as selective 5-HT(1A) agonists,J. Med. Chem. 47, 4677-4683, 2004
  • T. Heinrich, H. Böttcher, K. Schiemann, G. Hölzemann, M. Schwarz, Gerd D. Bartoszyk, C. van Amsterdam, H. E. Greiner and C. A. Seyfried,Dual 5-HT1A agonists and 5-HT re-uptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity,Bioorg. Med. Chem. 12, 4843-4852, 2004
  • G. D. Bartoszyk, C. van Amsterdam, H. E. Greiner, W. Rautenberg, H. Russ andC. A. Seyfried,Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand,1. Neurochemical profile,J. Neural Transm. 111, 113-126, 2004
  • G. D. Bartoszyk, C. van Amsterdam, H. Böttcher and C. A. Seyfried,EMD 281014, a new selective serotonin 5-HT2A receptor antagonist,Eur. J. Pharmacol. 273, 227-228, 2003
  • L. Matzen, C. van Amsterdam, W. Rautenberg, H. E. Greiner, J. Harting, C. A. Seyfried and H. Böttcher,5-HT reuptake inhibitors with 5-HT1B/1D antagonistic activity: a new approach toward efficient antidepressants,J. Med. Chem. 43, 1149-1157, 2000
  • Y. Liao, H. Böttcher, J. Harting, H. Greiner, C. van Amsterdam, T. Cremers, J. März, S. Sundell, M. Lundmark and H. Wikström,New selective and potent 5-HT1B/1D antagonists: chemistry and pharmacologic evaluation of N-piperazinylphenyl biphenyl-carboximides or -sulfonamides,J. Med. Chem. 43, 517-525, 2000
  • M. M. Mensonides-Harsema, Y. Liao, D. Dijkstra, H. Böttcher, L. Matzen, H. E. Greiner, C. van Amsterdam, J. Harting, C. A. Seyfried and H. V. Wikström,Synthesis and pharmacological properties of several related analogues of 5-HT-1B/1D selective GR127935,Society for Neuroscience Abstracts 24, 1109, 438.14, 1998
  • C. van Amsterdam, P. Misslin and M. Lemaire,Microdialysis measurements of free drug concentrations in blood and brainin: A. G. de Boer and W. Sutanto (eds.) Drug transport across the blood-brain barrier, 137-147,Harwood Academic Publishers, Amsterdam, 1997 
  • C. van Amsterdam and M. Lemaire,Pharmacokinetic profile of SDZ EAA 494 in blood, brain and CSF using microdialysis,Eur. J. Pharm. Sci. 5, 109-116, 1997
  • B. Ferger, E.-C. Zorn, C. van Amsterdam, C. Seyfried and K. Kuschinsky,In vivo evaluation of free radical production after glutamate stimulation and possible free radical trapping with PBN and selegeline in the striatum of rats,Naunyn-Schmiedeberg’s Arch. Pharmacol. 355 (Suppl), R88, 1997
  • B. Ofner, A. Boukhabza, W. Pacha, C. van Amsterdam and R. Wintersteiger,Determination of SDZ ICM 567 in blood and muscle microdialysis samples by microbore liquid chromatography with ultraviolet and fluorescence detection,J. Chromatogr. B 700, 191-200, 1997
  • B. Ferger, C. van Amsterdam, C. Seyfried and K. Kuschinsky,Effects of -phenyl-tert-butyl-nitrone (PBN) and selegeline on hydroxyl free radicals in rat striatum produced by local application of glutamate,J. Neurochem. 70, 276-280, 1996
  • C. van Amsterdam, A. Boukhabza, B. Ofner, W. Pacha and M. Lemaire,Measurement of free concentration of SDZ ICM 567 in blood and muscle using microdialysis sampling,Biopharm. Drug Dispos. 16, 521-527, 1995

Contributions to Congresses

  • C. van Amsterdam and M. Lemaire,Pharmacokinetic profile of  SDZ EAA 494 in blood, brain and CSF using microdialysis,2. International Symposium on Drug Transport to the Brain, 02.-04.02.1995, Amsterdam, The Netherlands
  • C. van Amsterdam and M. Lemaire,Equal distribution of free SDZ NDD 094 in blood, brain ECF and CSF 1995 Cerebral Vascular Biology Conference, 10.-12.07.1995, Paris, France
  • C. van Amsterdam, P. Guntz, A. Bruelisauer and M. Lemaire,Distribution of SDZ NDD 094 between brain compartments, CSF and blood23. Meeting of the Federation of European Biochemical Societies, 13.-18.08.1995, Basle, Switzerland
  • C. van Amsterdam, R. Laplanche, C. Nuez, A. Bruelisauer and M. Lemaire,Evaluation of hepatic and intestinal first-pass by means of portal vein microdialysis sampling,6. European Congress of Biopharmaceutics and Pharmacokinetics, 22.-24.04.1996, Athens, Greek
  • L. Matzen, C. van Amsterdam, W. Rautenberg, H. E. Greiner, J. Harting, C. A. Seyfried and H. Böttcher,Potent 5-HT reuptake inhibitors with 5-HT1B/1D antagonistic activity - new potential antidepressants,XVth International Symposium on Medicinal Chemistry,06.-10.09.1998, Edinburgh, Scottland
  • Y. Liao, H. Böttcher, J. Harting, H. E. Greiner, C. van Amsterdam, T. Cremers, G. Barnickel, J. März, M. Lundmark, S. Sundell and H. V. Wikström,New selective and potent 5-HT1B/1D antagonists: Chemistry, modeling and pharmacological evaluation,XVth International Symposium on Medicinal Chemistry,06.-10.09.1998, Edinburgh, Scottland
  • M. M. Mensonides-Harsema, , T. Cremers, H. Böttcher, H. E. Greiner, C. van Amsterdam, W. Rautenberg, C. A. Seyfried and H. V. Wikström,Synthesis and pharmacological properties of some related analogues of mirtazapine,XVth International Symposium on Medicinal Chemistry,06.-10.09.1998, Edinburgh, Scottland
  • J. H. Kehne, G. D. Bartoszyk, H. E. Greiner, K. A. Pierz, M. J. Renda, C. van Amsterdam, C. R. Reed and M. C. Athanasiou,In vitro characterization of Vilazodone as a dual-acting serotonin reuaptake inhibitor and 5-HT1A receptor partial agonist,65th Annual Meeting of the Society of Biological Psychiatry20. – 22.05.2010, New Orleans, Louisiana, U.S.A.
  • A.Jonczyk, D. Dorsch, G. Hölzemann, H. Greiner, F. Zenke, M. Meyring, C. Weber, M. Jacobs, C. van Amsterdam, D. Musil, P. Czodrowski, A. Wegener, J. Bomke, C. Amendt,Discovery of a novel naphthyridine inhibitor family of ALK-5,ASMC 13, 5th International Symposium on Advances in Synthetic and Medicinal Chemistry , 05. – 08.05.2013, Moscow, Russia
  • C. Heers, C. van Amsterdam, C. Habermann, H.Schauerte, H. van der Linde, H. Himmel, M. Traebert, T. Dinklo.,IRWIN/FOB tests for CNS safety assessment: what are we doing?,J Pharm Tox Meth 81, 338, 2016
  • H. Himmel, A. Delaunois, M. Deurinck, T. Dinklo, T. M. Eriksson Faelker, C. Habermann, C. Heers, K. Hempel, A. Rosch, H. G. Teuns, M. Traebert, C. van Amsterdam, H. van der Linde.,Inter-company reproducibility of Irwin/FOB CNS safety assessment following reference drugs chlorpromazine and amphetamine,15th Annual Meeting of the Safety Pharmacology Society,23. – 27.09.2017, Berlin, Germany

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement